BDX Teams Again With JDRF - Analyst Blog

By
A A A

Medical technology major Becton, Dickinson and Company ( BDX ) and JDRF reported that together they are hastening the creation of new offerings that amalgamate Becton's glucose monitoring and insulin infusion expertise. The latest 3-year agreement builds upon a pre-existing relationship between the two parties to tackle type 1 diabetes.

JDRF is the biggest charitable financier for research into type 1 diabetes. It aims to eventually eliminate type 1 diabetes. In 2012, JDRF provided over $110 million for type 1 diabetes research. It is at present the sponsor of $530 million in scientific study in 17 nations.    

Those suffering from type 1 diabetes use an insulin pump to receive insulin which requires usage of a catheter. They must also monitor the level of glucose by using a continuous glucose monitoring device, which again requires a catheter-type sensor.

BDX and JDRF will strive to create a solitary device which will carry out both functions, without requiring catheters. This capability to carry out separate metabolic processes in a systematic manner, while curtailing human interference, leads to the concept of an artificial pancreas.  

We remain cautious about Becton Dickinson due to the lack of major short-term catalysts. The rising demand for safety-needle products (with higher price points and margins) was the primary driver of the company's past growth. This is not expected to continue, given that the U.S. market is already largely penetrated.

On the positive side, Becton Dickinson's preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.

The stock retains a Zacks Rank #3 (Hold). We are more positive about other stocks. CONMED Corporation ( CNMD ), Heartware International Inc. ( HTWR ) and The Cooper Companies Inc. ( COO ) each carry a Zacks Rank #2 (Buy) and are expected to do well.



BECTON DICKINSO (BDX): Free Stock Analysis Report

CONMED CORP (CNMD): Free Stock Analysis Report

COOPER COS (COO): Free Stock Analysis Report

HEARTWARE INTL (HTWR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BDX , CNMD , COO , HTWR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

66,951,315
  • $74.15 ▼ 2.25%
60,109,543
  • $9.42 ▼ 5.80%
45,388,537
  • $17.045 ▲ 0.32%
35,062,961
  • $41.80 ▼ 0.67%
33,786,301
  • $32.64 ▼ 3.77%
33,624,242
  • $11.48 ▲ 2.41%
28,666,868
  • $4.63 ▼ 13.94%
27,853,554
  • $106.85 ▼ 0.46%
As of 10/30/2014, 02:22 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com